Cobra Biologics steps up work to develop Covid-19 vaccine with new manufacturing agreement

24
0

A North Staffordshire biologics business has entered a collaboration which will see it manufacture a Covid-19 vaccine for an Oxford-based medical firm.

Keele-based Cobra Biologics has signed a good manufacturing practice (GMP) agreement with Scancell for the production of a new vaccine which has the potential to provide long-lasting immunity against Covid-19 – by generating protection not only against this strain, but also against new strains of coronavirus that may arise in the future.

The project – which is being funded by an Innovate UK grant – represents a crucial development in the production of a Covid-19 vaccine for use in the Phase 1 clinical trial, COVIDITY.

The initial steps of GMP manufacture are scheduled to start imminently.

BusinessLive is your home for business news from around the country – and you can stay in touch with all the latest news through our email alerts.

You can sign up to receive daily morning news bulletins from every region we cover and to weekly email bulletins covering key economic sectors from manufacturing to technology and enterprise. And we’ll send out breaking news alerts for any stories we think you can’t miss.

Visit our email preference centre to sign up to all the latest news from BusinessLive.

Peter Coleman, Cobra Biologics CEO, said: “We are excited by this further collaboration with Scancell, with whom we share a long-standing relationship, to provide plasmid DNA for a promising new vaccine and its Phase 1 clinical trial.

“Our in-house expertise in quality assurance and production will ensure the delivery of GMP quality plasmid and we have great faith that Scancell’s DNA vaccine will show promise against SARS-CoV-2.”

Cobra Biologics has already signed a supply agreement with global pharmaceutical giant AstraZeneca for the manufacture of the AZD1222 vaccine to combat Covid-19.

Dr Cliff Holloway, CEO at Scancell, said: “Our collaboration with Cobra is critical to us moving forward with our novel SARS-CoV-2 vaccine into the planned Phase 1 clinical trial, COVIDITY.

“Cobra has the expertise needed to produce clinical grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness and protection against COVID-19.”


Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here